COVID booster needed for broad protection against omicron variants
Studies: 3rd dose generates enough antibodies for BA.2, deltacron, new sublineages
A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.
Researchers tested neutralizing antibody levels against the BA.2 and BA.3 omicron variants and deltacron, a recombinant variant created by the exchange of genetic material between delta and omicron.
Results showed that a third mRNA vaccine dose was required to generate a high enough concentration of antibodies to neutralize BA.2 and deltacron, as well as other sublineage omicron variants, including the original, known as BA.1, and BA.1.1. Antibodies produced by just the two-dose series of mRNA vaccines were enough to neutralize BA.3 – a sign this variant is not likely to produce a new surge of omicron infections, researchers say.
These findings were published today (May 18, 2022) in a letter to the editor of the New England Journal of Medicine (NEJM), and in an article published in Cell Host & Microbe on April 25, by a group of Ohio State University researchers.
“Three doses is better for everything,” said Shan-Lu Liu, the senior author of both studies and a virology professor in the Department of Veterinary Biosciences at Ohio State.
Recent national data have suggested that the BA.2 variant constitutes about 90% of COVID-19 cases in the United States.
“People have been asking about the recombinant deltacron and also BA.3, and now we have an answer. And it’s good news,” said Liu, also associate director of the university’s Center for Retrovirus Research and a program co-director of the Viruses and Emerging Pathogens Program in Ohio State’s Infectious Diseases Institute.
“Based on the neutralization pattern, one booster shot can protect against BA.2 and deltacron, and we do not suspect that BA.3 will become predominant because it’s sensitive to neutralization by even two doses.”
In the study published in NEJM, researchers tested antibody levels in serum from 10 health care professionals at Ohio State’s Wexner Medical Center. After two vaccine doses, on average, antibody levels were 3.3-fold and 44.7-fold lower against BA.3 and deltacron, respectively, than those that neutralized the parent SARS-CoV-2 virus. After the booster, antibody levels were much higher against all variants tested, and the same antibody level reductions were 2.9-fold and 13.3-fold – showing a dramatic improvement in protection, particularly against deltacron.
Next examining blood samples from 18 patients in the ICU during the delta wave of the pandemic, the researchers found comparable levels of antibodies against the parent virus and BA.3, but 137.8-fold lower concentrations against deltacron compared to the parent virus. Blood samples from 31 hospitalized non-ICU patients during the omicron surge showed much better antibody protection against deltacron.
“The deltacron spike protein is structured similarly to other omicron variants, so people infected with omicron seem to have pretty good protection against deltacron. But people infected with delta had pretty weak protection against deltacron,” said John Evans, a PhD candidate in Ohio State’s Molecular, Cellular and Developmental Biology Program who works in Liu’s lab, and the first author of the new studies. “However, compared to the booster, infection by omicron provides much less protection against deltacron.”
The Cell Host & Microbe study tested antibody levels in serum from 48 health care professionals after their second mRNA vaccine dose and from 19 after their third mRNA vaccine doses, as well as 31 COVID-19 patients hospitalized during the omicron surge.
“For two vaccine doses, health care workers had very weak neutralizing antibody concentrations against the omicron variants, but after the booster it evened out,” Evans said. “The neutralizing antibody levels were still lower against omicron compared to the parental virus, but much more comparable across variants and much higher. So the booster provides much stronger protection and much broader protection.”
Patients with delta or omicron infection were similarly protected against their respective infectious variants, and a vaccine dose on top of infection improved protection. Among all of the health care professionals and infected patients studied, people who had received three vaccine doses had the broadest and strongest antibody protection overall.
The researchers conducted the cell-culture studies using pseudoviruses – a non-infectious viral core decorated with different SARS-CoV-2 spike proteins on the surface structured to match known mutations. The method used to detect neutralizing antibodies in the blood samples accounted for the varying concentrations of antibodies produced by individuals.
Liu and colleagues have completed additional tests of neutralizing antibody responses to the BA.2.12.1, BA.4 and BA.5 omicron sublineages, which are growing in dominance among newly reported cases. In a paper posted May 17 on the bioRxiv preprint server (and published in the New England Journal of Medicine on June 15), they described similar findings: A booster provided sufficient antibody concentrations against these three additional omicron subvariants, though to a lower extent than protection seen for BA.1 and BA.2, and previous omicron infection did not offer effective antibody protection against these variants.
Liu’s lab is continuing this work, investigating how long antibody protection from the third booster shot lasts. Waning antibody levels seen in blood samples collected the furthest out from the third dose suggest there is a limit to the first booster’s durability, Liu said.
“The virus is evolving, which is typical for all RNA viruses, and what we have seen is not surprising at all,” Liu said. “Especially when we have lots of variants in the population, anything can happen, including recombination between them. That’s why we still need to be very cautious. The best preparation is to get the second booster.”
This work was supported by anonymous donor funds, grants from the National Institutes of Health, the National Center for Advancing Translational Sciences, the Glenn Barber Fellowship from Ohio State’s College of Veterinary Medicine, the National Cancer Institute and the Robert J. Anthony Fund for Cardiovascular Research. Liu also acknowledged the generosity of the health professionals and patients who participated in the studies.
Additional co-authors on both papers include Cong Zeng, Panke Qu and Yi-Min Zheng of the Center for Retrovirus Research; Linda Saif of Ohio State’s Center for Food Animal Health; and Claire Carlin, Joseph Bednash, Gerard Lozanski, Rama Mallampalli, Eugene Oltz, Peter Mohler and Richard Gumina of Ohio State’s College of Medicine. Virus researchers Julia Faraone, Xue Zou and Kai Xu of Ohio State and Tongqing Zhou of the NIH were co-authors on the Cell Host & Microbe paper and the preprint.